A Phase I, Single-center, Randomized, Open-label, 2-cycle,2-period Crossover Study to Evaluate the Food Effect on the Pharmacokinetics of JAB-21822 in Healthy Subjects
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Glecirasib (Primary)
- Indications Colorectal cancer; Intestinal cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Jacobio Pharmaceuticals
- 03 Jan 2024 Status changed from active, no longer recruiting to completed.
- 18 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Status changed from not yet recruiting to recruiting.